Chen X, Tang P, Kong Y, Chen D, Tang K
J Cancer Res Clin Oncol. 2024; 150(2):61.
PMID: 38300336
PMC: 10834659.
DOI: 10.1007/s00432-024-05612-w.
Zia M, Parveen S, Shafiq N, Rashid M, Farooq A, Dauelbait M
ACS Omega. 2024; 9(2):2161-2182.
PMID: 38250382
PMC: 10795055.
DOI: 10.1021/acsomega.3c05098.
Rhiem K, Zachariae S, Waha A, Grill S, Hester A, Golatta M
Breast Care (Basel). 2023; 18(2):106-112.
PMID: 37261134
PMC: 10228253.
DOI: 10.1159/000528972.
Khan N, Wang D, Wang W, Shahid M, Khattak S, Ngowi E
Molecules. 2022; 27(13).
PMID: 35807290
PMC: 9268373.
DOI: 10.3390/molecules27134049.
Jia T, Liu Y, Fan Y, Wang L, Jiang E
Front Public Health. 2022; 10:797794.
PMID: 35400043
PMC: 8984028.
DOI: 10.3389/fpubh.2022.797794.
Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland.
Zlowocka-Perlowska E, Toloczko-Grabarek A, Narod S, Lubinski J
Hered Cancer Clin Pract. 2022; 20(1):13.
PMID: 35395863
PMC: 8994347.
DOI: 10.1186/s13053-022-00220-6.
No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in or Mutation Families.
Imbert-Bouteille M, Corsini C, Picot M, Mizrahy L, Akouete S, Huguet H
Genes (Basel). 2021; 12(7).
PMID: 34356116
PMC: 8305427.
DOI: 10.3390/genes12071100.
Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
Jimenez-Sainz J, Jensen R
Genes (Basel). 2021; 12(5).
PMID: 34065235
PMC: 8161351.
DOI: 10.3390/genes12050780.
Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
Romero I, Leskela S, Perez Mies B, Velasco A, Palacios J
EJC Suppl. 2020; 15:1-15.
PMID: 33240438
PMC: 7573476.
DOI: 10.1016/j.ejcsup.2020.02.001.
Prevalence and Spectrum of Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study.
Foglietta J, Ludovini V, Bianconi F, Pistola L, Reda M, Al-Refaie A
Genes (Basel). 2020; 11(8).
PMID: 32806537
PMC: 7464094.
DOI: 10.3390/genes11080925.
Association of Tagging Single Nucleotide Polymorphisms With Breast Cancer in a Sample of Colombian Population: A Case Control Study.
Beltran A, Benitez E, Rondon M, Ariza Y, Aristizabal F, Briceno I
Breast Cancer (Auckl). 2020; 14:1178223420904939.
PMID: 32341648
PMC: 7172001.
DOI: 10.1177/1178223420904939.
PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells.
Quinet A, Tirman S, Jackson J, Svikovic S, Lemacon D, Carvajal-Maldonado D
Mol Cell. 2019; 77(3):461-474.e9.
PMID: 31676232
PMC: 7007862.
DOI: 10.1016/j.molcel.2019.10.008.
Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado L, Tusie-Luna M, Tussie-Luna M, Diaz-Chavez J, Segura Y, Bargallo-Rocha E
BMC Cancer. 2019; 19(1):118.
PMID: 30709381
PMC: 6359755.
DOI: 10.1186/s12885-019-5312-2.
How best to protect the vital interests of donor-conceived individuals: prohibiting or mandating anonymity in gamete donations?.
de Melo-Martin I
Reprod Biomed Soc Online. 2018; 3:100-108.
PMID: 29774255
PMC: 5952682.
DOI: 10.1016/j.rbms.2017.01.003.
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C, Rhiem K, Hahnen E, Loibl S, Weber K, Seiler S
BMC Cancer. 2018; 18(1):265.
PMID: 29514593
PMC: 5842578.
DOI: 10.1186/s12885-018-4029-y.
The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?.
Teixeira N, van der Hout A, Oosterwijk J, Vos J, Devilee P, van Engelen K
Eur J Hum Genet. 2018; 26(6):848-857.
PMID: 29483665
PMC: 5974362.
DOI: 10.1038/s41431-018-0111-9.
MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells.
Lemacon D, Jackson J, Quinet A, Brickner J, Li S, Yazinski S
Nat Commun. 2017; 8(1):860.
PMID: 29038425
PMC: 5643552.
DOI: 10.1038/s41467-017-01180-5.
Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L, Zidan O, Friedman E, Kalfon S, Perri T, Ben-Baruch G
J Gynecol Oncol. 2017; 28(5):e61.
PMID: 28657222
PMC: 5540720.
DOI: 10.3802/jgo.2017.28.e61.
Germline Mutations in Triple-Negative Breast Cancer.
Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler R
Breast Care (Basel). 2017; 12(1):15-19.
PMID: 28611536
PMC: 5465748.
DOI: 10.1159/000455999.
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation.
Toss A, Grandi G, Cagnacci A, Marcheselli L, Pavesi S, De Matteis E
Oncotarget. 2016; 8(6):9144-9154.
PMID: 27880720
PMC: 5354721.
DOI: 10.18632/oncotarget.13423.